NEW YORK, June 26, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Universal Health Services Inc. (NYSE: UHS), Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Northwest Biotherapeutics, Inc. (NASDAQ: NWBO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4130-100free.
--
Universal Health Services Inc. Analyst Notes
On June 23, 2014, Universal Health Services, Inc.'s (Universal Health Services) stock increased 1.74% to end the day at $98.75. The Company's stock climbed 3.57% over the past three trading days compared to the Dow Jones Industrial Average which rose 0.18% and to S&P 500 which gained 0.29% during the same trading period. The full analyst notes on Universal Health Services are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/UHS/report.pdf
--
Brookdale Senior Living Inc. Analyst Notes
On June 23, 2014, Brookdale Senior Living, Inc.'s (Brookdale) stock increased 1.07% to end the day at $33.87. The Company's stock increased 3.70% over the past five trading days compared to the Dow Jones Industrial Average which rose 0.93% and to S&P 500 which moved up 1.28% during the same trading period. The full analyst notes on Brookdale are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/BKD/report.pdf
--
Envision Healthcare Holdings, Inc. Analyst Notes
On June 18, 2014, Envision Healthcare Holdings, Inc. (Envision Healthcare) announced that its EmCare division has completed the acquisition of Phoenix Physicians, LLC. According to the Company, the acquisition is anticipated to add approximately $125 million in revenues and approximately 800,000 patient encounters annually. The Company informed that Phoenix Physicians provides services to 21 hospitals in six states, including Broward Health, one of the largest health systems in the nation. The Company added that the Physicians services includes emergency department, urgent care facility, adult and pediatric hospitalist, OB/GYN and high-risk perinatal services in Florida, North Carolina, New Jersey, Arkansas, Ohio and Virginia. The full analyst notes on Envision Healthcare are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/EVHC/report.pdf
--
Karyopharm Therapeutics, Inc. Analyst Notes
On June 16, 2014, Karyopharm Therapeutics, Inc. (Karyopharm) announced that the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has found the effectiveness and safety technical sections complete to support conditional approval under a New Animal Drug Application (NADA) for Karyopharm's, oral Selective Inhibitor of Nuclear Transport (SINE) compound -Verdinexor (KPT-335) for the treatment of canine lymphoma. The Company informed that it has submitted the effectiveness and safety technical sections of the NADA for Verdinexor to FDA as part of a phased review approach to approval. Dr. Sharon Shacham, Karyopharm's Founder, President and Chief Scientific Officer said, "We are very pleased that FDA has found Verdinexor to be safe and have a reasonable expectation of effectiveness for treating lymphoma in client owned dogs." The full analyst notes on Karyopharm are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/KPTI/report.pdf
--
Northwest Biotherapeutics, Inc. Analyst Notes
On June 16, 2014, Northwest Biotherapeutics, Inc. (NW Bio) announced that with effect from June 27, 2014, the Company has been added to two notable Russell Indexes- the Russell Global and the Russell 3,000 Indexes. Linda Powers, CEO of NW Bio commented, "We are very gratified to be added to both the Russell Global and the Russell 3000 Indexes. It is an important reflection of NW Bios strong progress and accelerating momentum on multiple fronts (both on the science and clinical fronts and on the business and finance fronts)." According to the Company, the selection for the inclusion in these indexes is based upon market capitalization and other market factors relating to a company and its stock. The Company further stated that membership in these indexes is updated annually, and remains in place for one year. The full analyst notes on NW Bio are available to download free of charge at:
http://www.analystsreview.com/Jun-26-2014/NWBO/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
